For California-based PharmaCyte Biotech, Inc. (OTCQB: PMCB), a light at the end of the pipeline tunnel has become visible as one piece of good news follows another. The approval by the FDA to entertain a Pre-Investigational New Drug (Pre-IND) submission from the company sent PMCB stock soaring to triple its pre-approval value. The resulting market cap made PharmaCyte ‘primarily eligible’ to register securities for sale in an at-the-market (ATM) offering, which it now plans to do through Chardan Capital.

To make an ATM offering requires that the issuer be eligible, on a primary basis, to use a shelf registration statement on Form S-3. The Form S-3 filing initiates an equity distribution program under which, from time to time, ATM offerings can be made. Each ATM offering is a drawdown from the related shelf registration securities offering.

ATM offerings have a number of advantages. They typically cost less than traditional follow-on offerings, particularly since they are executed without high profile, expensive road shows. They also give an issuer the flexibility to determine the timing and size of any share sale, while allowing shares to ‘trickle’ into the market in a way that does not adversely affect the stock price.

PharmaCyte is now primarily eligible to use Form S-3 to offer securities, on its own behalf, for cash on an unlimited basis in ATM offerings, since the aggregate market value of its voting and non-voting common equity held by non-affiliates (i.e., the public float) is at least $75 million. The company intends to use funds received from the ATM offerings to advance the clinical trial process of its signature live-cell encapsulation technology, Cell-in-a-Box®.

PharmaCyte will be submitting a full Pre-IND package of information to the FDA that will set out essential elements of its planned Investigational New Drug (IND) application. After which, the FDA will review PharmaCyte’s manufacturing, preclinical pharmacology and toxicology, and clinical trial plans for the company’s therapy to treat locally advanced pancreatic cancer (LAPC). On successful completion of the review, PharmaCyte will be able to proceed with enrolment of the first clinical trial.

PharmaCyte’s clinical trial for LAPC is designed to meet a clear unmet medical need for those whose cancer no longer responds after 4-6 months of treatment with the combination of Abraxane® and gemcitabine. The trial will be open-label and multi-site in nature, with sites in the U.S. and Europe. Patients with LAPC will be randomized equally into two groups. One group will receive gemcitabine chemotherapy alone, and the other will receive PharmaCyte’s pancreatic cancer therapy. In addition to comparing the anticancer activity and safety of the two therapies, a major aspect of the trial will be to determine if, and how well, PharmaCyte’s therapy can shrink inoperable tumors so that they may become operable.

To work on its novel technology, Cell-in-a-Box®, PharmaCyte has assembled a respected team of oncologists that includes leading pancreatic cancer expert Dr. Daniel Von Hoff from Translational Drug Development (TD2), Dr. Manuel Hidalgo from Harvard Medical School, and Dr. Matthias Löhr from the Karolinska Institute in Stockholm, Sweden.

PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. The Cell-in-a-Box® therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or anti-carcinogenic form.

These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to the location of the implanted encapsulated cells.

When the ifosfamide comes in contact with the encapsulated cells, they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This targeted chemotherapy has proven effective and safe to use in past clinical trials and results in no side effects.

For more information, visit www.pharmacyte.com

An innovative potential treatment for hepatic encephalopathy created by Ocera Therapeutics, Inc. (NASDAQ: OCRX) is a unique product on an under-served market, and if clinical trials are successful, it could become a major source of success and profitability for the company, according to an Aegis Capital Corp. report (http://dtn.fm/J0h97) released on December 8. The report reiterates a ‘Buy’ rating for Ocera and recommends a higher stock price target of $8, compared to the $2.1 at the time of the analysis.

The Aegis report was released a day after Ocera announced completion of enrollment in its phase 2B trials for lead product candidate OCR-002 – an acute treatment for hepatic encephalopathy and hyperammonemia in patients with acute liver injury, acute liver failure and liver cirrhosis. The phase 2B study, called STOP-HE, will evaluate the safety, efficacy and tolerability of OCR-002 (Ornithine Phenylacetate) in hospitalized patients suffering from hepatic encephalopathy. The study enrolls a total of 230 subjects, which will be administered either OCR-002 or a placebo intravenously for five days. Based on their degree of liver impairment, patients will be given various doses of the drug, ranging from 10 to 20 grams over a 24-hour period.

Top-line data are due in the first quarter of 2017, which Aegis experts expect will be a share inflection point for the company. The study’s primary goal is to archive a meaningful clinical improvement in hepatic encephalopathy symptoms, so as to keep OCR-002 on track to potentially becoming a first-line, foundational therapy of choice for patients with this condition, on a market with significant unmet medical needs. Hepatic encephalopathy is a progressive complication of liver failure of cirrhosis which is marked by partial cognitive impairment including disorientation, confusion and impaired motor skills, while more severe forms can lead to coma and even the patient’s death.

According to the Agis report, there are currently only two hepatic encephalopathy products on the market, with others in development. Lactulose is a first-line therapy that has the largest market share at the moment, while Rifaximin is a second-line therapy. But Aegis analysts believe that OCR-002 has great potential and can take a significant market share, being unique in several respects: it has a unique mechanism of action as an ammonia scavenger, it is the only drug that can be administered intravenously and it has the potential to significantly shorten hospital stays.

If the phase 2B trial is successful, OCR-002 could reach approximately 170,000 patients that have hepatic encephalopathy and require hospitalization. Aegis analysts expect the therapy to achieve at least 22 percent market share and yield revenues of approximately $150 million. Ocera is also developing an oral formulation of the drug for chronic use, with the goal of preventing hepatic encephalopathy recurrences. The oral formulation was not included in the Aegis analysis, but it may indeed help provide an even larger share of the market.

As for potential risks for investors as identified in the report, these include typical manufacturing, commercialization, research and development, and regulatory risks that generally result from investing in pharmaceutical companies. The analysis also points out a series of specific risks of investing into Ocera, such as relying on the success of OCR-002, the company’s liquidity and high volatility.

For more information, visit the company’s website at www.ocerainc.com

U.S. home prices are going up steadily, having reached the highest peak in September after 2006’s real estate boom, a growth primarily driven by rising demand and a scarce inventory. The price hike came as a surprise to most real estate professionals, who expected a significant market slowdown in the last few months of 2016. While 2017 is likely to see more moderate growth, the market will continue to expand nonetheless, Realtor.com (http://dtn.fm/HdG6u) experts believe, as two of America’s largest generations – Millennials and baby boomers, are reaching a stage in their lives that typically motivates people to buy a home.

With this growing demand and a consistently smaller inventory, finding the right home will become more difficult than ever. GainClients, Inc. (OTC: GCLT), a leading provider of technology solutions for the real estate industry, aims at helping consumers look for and identify the right home for them via a comprehensive yet easy-to-use online search platform called GC HomeSearch (http://dtn.fm/AOI6o). The company’s declared goal is to offer simplified home search tools by providing buyers with a lot more information with a lot less, in an effort to make the home search process as easy and enjoyable as possible.

Through the online platform, buyers can get accurate and realistic knowledge of the homes they’re looking at, as well as the areas they’re located. This includes information such as home values, neighboring schools and services, demographic statistics, detailed property and neighborhood information, and more. Users can search as many properties as they want after registering for a free account. Search results can be sorted by city, state or zip code, and interesting properties can be saved for later viewing. Users can even find homes in their vicinity be entering the word ‘nearby’ in the search box.

The GC HomeSearch platform currently lists almost one million residential homes, which is encouraging given dwindling inventory numbers nationwide. According to Realtor.com statistics, the inventory of homes for sale in the top 100 metropolitan markets is going down at an average rate of 11 percent year after year, a trend that’s likely to continue next year as well.

The platform is the only GainClients service destined primarily to consumers, not real estate professionals, and was built with the intention of serving as a real estate community to all home buyers looking for their ideal property. For more in-depth information and backstage access to intelligent home buying and selling tools such as loan payment and rates calculators and closing cost estimates, users can link their GC HomeSearch account with the company’s flagship product, the GCard (http://dtn.fm/mQx7D) real estate networking system.

The GCard was designed with the primary purpose of helping real estate professionals connect and better communicate with their customers and other industry experts. This platform, accessible via web, mobile web, text message and smartphone app, gives real estate agents and lenders, as well as insurance agents, the means of providing consumers with the information they want when they want it. Professionals using this service are also able to network with each other, with the end goal of providing improved service to their clients.

For more information, visit the company’s website at www.gainclients.com

Let us hear your thoughts: GainClients, Inc. Message Board

How does a start-up venture capital-backed company grow its revenues to nearly a billion dollars in the global spine industry in less than two decades? By developing a competitive advantage in Speed of Innovation® and Absolute Responsiveness®, two concepts that have made NuVasive, Inc. (NASDAQ: NUVA) the number three company in the spine industry with over 90 products in its portfolio, including lumbar, thoracic, and cervical applications; neuromonitoring services; and biologics solutions.

The global spinal implants and surgical devices market ‘is expected to reach USD 17.27 Billion by 2021, growing at a CAGR of 5.3% from 2016 to 2021’, according to a press release from MarketsandMarkets (http://dtn.fm/uHV0W). Increasing longevity and the resulting larger elderly population means more spinal disorders, such as herniated discs, degenerative disc disease, spondylolisthesis, prolapsed intervertebral discs, and spinal stenosis. In addition, the development of minimally invasive surgical (MIS) procedures is leading to wider adoption of technologically advanced spinal implants.

MIS is NuVasive’s forte. The company is best known for developing the eXtreme Lateral Interbody Fusion® (XLIF) procedure, a minimally disruptive procedure that allows spine surgeons to have direct access to the intervertebral disc space (the “joint” of the spine) from the side of the body, as opposed to the front or back. The XLIF procedure is just one of the company’s many innovative procedures, which have redefined spine surgery and opened doors to treat pathologies not previously treated with minimal disruption.

NuVasive has also developed a revolutionary nerve avoidance monitoring system (NVJJB™ /M5®) designed to help ensure nerve and spinal cord safety – this unique and advanced technology may help reduce the incidence of injury to neural elements during spinal procedures by providing real-time feedback and notifying surgeons immediately of any neurological insult. Additionally, NuVasive offers a portfolio of biologics products to help in the bone healing process.

A recent report from Aegis Capital (http://dtn.fm/H1sQC) suggests that NuVasive’s rapid growth is far from over. The company has been steadily paring manufacturing inefficiencies. As a consequence, gross profit has hovered around 75 percent. Other operating margin improvements are expected from economies of scope as the marketing offering expands and economies of scale form an increasingly larger international footprint. Aegis sees “900bp of operating improvements to come, which will continue to drive value.”

In a fast growing industry (2–3% p.a.), NuVasive, focused on developing minimally disruptive surgical products and procedures for the spine, is a fast growing company (2-3x faster than the overall market). The drivers of growth are its ‘expanding platform of offerings, adapting a holistic approach with regards to its sales effort, and increased Integrated Global Alignment (iGA) integration which allows better planning for deformity and saves cost.’

Alignment is one of three important factors to be considered when spine surgery is being contemplated. In cases of spondylolisthesis, for example, the first concern is usually decompression of the nerves to ease any pain or discomfort the patient may be experiencing. In many instances, this means removing the disc or other offending piece from the spine. The resulting space is, typically, filled by bone graft or a synthetic substance in a procedure known as lumbar interbody fusion (LIF). At this point, alignment procedures to straighten the spine may be implemented.

NuVasive, which has a presence in over 30 countries and employs more than 1,600 people globally, had revenues of $811 million in 2015. A 17 percent increase to $953 million is expected this year. Aegis has initiated coverage with a ‘Buy’ rating and a price target of $72.00. The stock, trading on the NASDAQ under the symbol NUVA, is currently around $67.00.

For more information, visit www.nuvasive.com

Nano Dimension Ltd. (NASDAQ: NNDM) is the holding company for Nano Dimension Technology Ltd., a company in the business of researching, developing, and manufacturing three-dimensional (3D) printers for printed circuit boards (PCBs). The company also develops nano ink materials and other products for electronics. NNDM has the vision of revolutionizing the way electronics are made with 3D printing by using 3D printers for multilayer PCBs, along with advanced nanotechnology-based conductive and dielectric inks.

Since the beginning of last year, Nano Dimension has won the Europe 2015 Award for Best Development in 3D Printing Equipment, the Gartner ‘Cool Vendor’ in 3D Printing 2016, and the TÜV SÜD Innovation 2016 award. NNDM is equipped with an experienced managerial team with a long background in the technology and 3D printing spaces, and the company is well-positioned to capitalize on the PCB prototyping industry, which is currently worth approximately $70 billion.

With the launch of its new DragonFly 2020 3D Printer to select beta customers in the U.S., Israel, and Germany, during the third and fourth quarters of this year, Nano Dimension Ltd. is expected to make sales on a more commercial level as early as 2017. The printer, which comes with specialized 3D software as well as conductive and dielectric inks, has now received attention from over 2,500 entities currently on the information waitlist. In addition, more than 30 NDAs have been signed to enable the collaboration and evaluation of this equipment.

With its new printer, Nano Dimension Ltd. plans to provide its clients with more advanced solutions than ever before while tapping into additional markets. Through the DragonFly 2020 3D Printer, Nano Dimension expects to meet the needs of additional market segments by offering faster solutions that print larger objects from a broader materials portfolio with functional inks.

According to The Daily Quint (http://dtn.fm/j5xiP), Nano Dimension has been the topic of conversation for several research analysts firms, receiving a consensus ‘Buy’ rating from five investment analysts with a consensus average price target of $12.60 per share. At close of market on December 13, 2016, the company’s shares were sold at an individual price of $6.05. NNDM’s market capitalization currently stands at $46.96 million.

For more information, visit www.nano-di.com

Before the opening bell, eXp World Holdings, Inc. (OTCQB: EXPI), the holding company for The Agent-Owned Cloud Brokerage®, announced its retention of MZ Group as its investor relations advisor. Moving forward, MZ Group will assist and advise EXPI regarding its ongoing communications with shareholders with the aim of strengthening the company’s public brand and broadening its investor base.

“We have chosen to partner with MZ Group to bolster our investor relations and outreach efforts during this time of rapid growth within our Company,” Glenn Sanford, founder, CEO and chairman of EXPI, stated in this morning’s news release. “While we have more than doubled in size over the past year due in large part to the dedicated efforts of our existing agent and broker network, we believe there is room for sustained growth as we continue to invest in our core infrastructure and agent and broker network.”

In recent months, EXPI, through the expansion of subsidiary eXp Realty, has recorded strong growth in terms of both market reach and financial results. As of its latest report, the company’s real estate brokerage division had more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. This marks an increase of nearly 155 percent from the beginning of 2016, when eXp Realty reported just 864 agents.

This market growth has translated into strong financial performance for EXPI in 2016, demonstrating the viability of the company’s current growth strategy. Last month, EXPI released its financial results for the third quarter of 2016, which included a 112 percent year-over-year increase in total revenues to $15.7 million. In the update, the company’s management team attributed this increase to eXp Realty’s growing sales agent base and the resulting rise to sales volume being generated by the real estate brokerage division.

EXPI’s share price has been on a similarly-promising upward trend throughout much of 2016. In January, the company’s PPS hovered around $0.84. By October, EXPI’s common stock climbed to a record high of more than $5.80 following the announcement of a new strategic partnership with Commissions, Inc., a leading provider of web-based real estate marketing and CRM software. The company’s stock is currently trading at around $4.35 per share.

News of EXPI’s retention of MZ Group comes just days after the company’s real estate brokerage division was recognized as a winner of the Oklahoma 2016 Top Workplaces Award by The Oklahoman newspaper. eXp Realty has previously received similar recognition in both Washington, D.C. and Atlanta for its commitment to creating a collaborative, engaging and rewarding work environment.

For more information, visit the company’s website at www.eXpWorldHoldings.com

Let us hear your thoughts: eXp World Holdings, Inc. Message Board

PRO 140, an innovative new therapy for HIV patients developed by Cytodyn Inc. (OTCQB: CYDY), is currently undergoing phase 3 clinical trials, having been administered to several patients, according to a company press release (http://dtn.fm/F40vr). No other details were provided about the initial results of phase 3 trials, but a separate report said actor Charlie Sheen is one of the subjects and that he has achieved undetectable viral load after taking PRO 140.

Sheen, who revealed his HIV status in November last year, has been a part of the study for eight months and is receiving weekly injections of the drug, the report said. The phase 3 study is looking into PRO 140’s safety and effectiveness in HIV patients and is being administered without any other HIV medication to determine whether it alone is enough to fight HIV and help subjects achieve an undetectable viral load.

Cytodyn, a biotech company that focuses on the development of innovative antibody therapies against the human immunodeficiency virus and other diseases, has not officially commented on the Daily Mail report. In a press release this week, however, it announced that several patients have already been treated with PRO 140 as part of the phase 3, multicenter clinical trial which will enroll a total of 300 subjects. All the patients included in the study have CCR5-tropic HIV-1 infection and are clinically stable, being on highly active antiretroviral therapy up to one week after the enrollment.

During the phase 3 trial, the subjects will receive only PRO 140 in the form of subcutaneous injections for 48 weeks to determine whether the product candidate is safe and efficient as a single-agent maintenance therapy for chronic suppression of HIV. PRO 140 is a fully humanized monoclonal antibody that specifically targets the CCR5 entry receptor on CD4 cells, which HIV targets and takes over. The proprietary therapy fights HIV by blocking this entry point and preventing the virus from infecting healthy cells.

CytoDyn CEO and President Nader Pourhassan, Ph.D. said his company expects the monotherapy trial to yield significant results and provide sufficient data to support further clinical and regulatory advancement of the treatment. He explained that the phase 3 trial is nearly a duplicate of the phase 2b trial that ended last year, with an additional objective of determining why some R5 patients are not responding to the therapy as well as others. Out of 15 subjects who continued the trial in the extension arm and received weekly PRO 140 injections in phase 2b trials, 10 maintained an undetectable viral load for more than two years, while four others did not report any changes in their HIV infection. The last patient moved away and could not be monitored.

Pourhassan is confident that the phase 3 trial findings will help determine which patients can achieve long-term HIV suppression and ultimately secure label expansion for PRO 140 as a single agent therapy, given it has low toxicity and virtually no side effects. PRO 140 only targets HIV patients with the R5 strain, Pourhassan added. This strain currently accounts for about 70 percent of HIV infections and 90 percent of newly-diagnosed cases in the United States.

For more information, visit www.cytodyn.com

Moxian, Inc. (NASDAQ: MOXC), a top digital marketing company, uses powerful social media-driven marketing and sales tools to connect online users and merchants. Backed by a flourishing online-to-offline integrated platform, this company offers offline merchants solid opportunities to strengthen their outreach to digital consumers.

Since it was founded in 2013, Moxian has catered to one particular business pain: the merchant’s need to engage with more digitally-savvy consumers. Along the way, this offline-to-online integrated platform operator has expanded from managing its operations from its base in Shenzhen, China, to creating branch offices in Beijing, Malaysia and Hong Kong.

Following the Nasdaq listing of its stock in November 2016 and the official launch of its Moxian+ App in recent months, Moxian is embarking on a new chapter. The company’s Moxian+ mobile application platform connects users to merchant clients through entertaining games, rewards and social events. In return, users provide valuable information that Moxian’s merchant clients can use to successfully market products and services sold at their brick and mortar stores.

From the start, Moxian has designed its products and services to allow merchant clients to run advertising campaigns and promotions targeting potential customers. Its platform was also developed and built to encourage current users to return frequently and to persuade new users to subscribe to its website. Now, Moxian is fully engaged in delivering products and services that compile user data into a comprehensive database, one that allows merchants to study and better understand user behavior and, in turn, improve their dealings with those users.

Over the years, Moxian has also moved beyond focusing on the domestic market in China to the global market as a whole. It has done so by establishing tactical data centers in both China and Singapore. At its data center in China, the company is leveraging the Oracle Exadata Database Machine in a private cloud environment in order to improve database computing, maximize database performance on the cloud platform and further save storage space and cost. And at its data center in Singapore, it is using the Oracle Database Appliance to boost database performance and lower overall investment cost with Flash, memory planning and other smart data technologies.

For more information, visit the company’s website at www.Moxian.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.net

According to 4Hoteliers (http://dtn.fm/zOeA9), 85% of travelers across the world are also smartphone users. The article goes on to state that 32% of these travelers use their mobile devices to book travel-related services. The company’s recent webinar, ‘Digital Marketing and Mobile Trends Impacting the Travel Industry’, showed that over 70% of travelers use mobile devices to check their itineraries.

But the increase in mobile usage for travel is not all that is impacting the industry. A more experience-based economy, the new social ecosystem we live in, and the growing preference for recommendations from peers are just some of the digital marketing trends transforming the travel industry, according to Smart Insights (http://dtn.fm/DoC4q). Because travel arrangements are now largely made via the Internet, and the typical consumer is looking for more than just a basic holiday, organizations in the travel industry are having to adapt to a more digital and mobile way of reaching consumers.

During a survey undertaken by Opera Mediaworks (http://dtn.fm/J9gWx), one in three people said that the availability of booking apps would make them more likely to book via mobile, and one in three also said that having research apps available could make them more likely to engage in more travel activities such as eating out, visiting various sights, and more. According to the ‘How People Use Their Phones For Travel’ research published by Google (http://dtn.fm/B5iX2), the top motivating factor for downloading travel apps is to make a specific activity or task easier. Users shared that what they find most valuable about travel apps is the wide range of features and the fact that apps store preferences that make future activities easier.

As a result, NextTrip.com, flagship company of Monaker Group, Inc. (OTCQB: MKGI), designed its own all-in-one travel planner, which gives travelers access to a range of free tools that allow them to import all booking details into one space. The free travel organizer allows users to discover hotels, restaurants, sights, and activities near their points of interest. The all-in-one travel planner helps holidaymakers organize details of their trips, and even split and collect money between groups of people. NextTrip’s travel planner is easy to use, easily accessible, and makes planning a trip while on the move simple thanks to its compatibility with mobile devices.

For more information, visit www.MonakerGroup.com

Let us hear your thoughts: Monaker Group, Inc. Message Board

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company in the business of developing, manufacturing, and globally commercializing products that treat severe burns and wounds. In 2012, MediWound’s innovative drug, NexoBrid™, a burn and wound eschar removal agent, was approved by the European Medicines Agency (EMA) via a centralized procedure. The drug was given orphan indication for removal of dead and damaged skin in adults with burns that are deep partial and full thickness thermal burns.

NexoBrid™ was launched throughout Europe and is now being used in patients with hospitalized burns and wounds. MediWound has initiated phase III clinical trials on NexoBrid™ in the U.S. and pediatric study. The company also has two other products in its pipeline: EscharEx, which is in its phase II study and is for use in patients with chronic wounds, and MWPC003, which is about to enter its phase I study and is for use in patients with connective tissues disorders.

In November of this year, MediWound Ltd. announced third quarter 2016 financial results for the three- and nine-month periods ended September 30, 2016. The company reported revenue for the quarter of $518,000, compared to just over $100,000 for the same quarter of 2015. This was put down to the growing sales of NexoBrid™. The nine-month period results showed total revenue of $1.1 million, compared to $0.3 million for the same nine-month period of the previous year. MDWD will be spending the remainder of 2016 investing primarily in sales and marketing activities relating to the further adoption of NexoBrid™ in Europe.

Aegis Capital Corp. (http://dtn.fm/l63Bn) initiated coverage on MediWound Ltd., giving the company a ‘Buy’ rating with a price target of $11 per share. This rating was given based on the fact that the company has made significant progress in the area of wound debridement. According to the report, MDWD’s NexoBrid™ is showing significantly faster, more selective, safer, and more cost efficient results compared to current treatments. The report also highlights the possibility for the company to integrate into the chronic wound care market with EscharEx and markets relating to connective tissue disorders with its pipeline product MWPC003.

Despite Zacks Investment Research lowering the company’s status from a ‘Buy’ rating to a ‘Hold’ rating, six other research analysts have given MDWD a ‘Buy’ rating, and Wells Fargo & Co. offered MediWound an ‘Outperform’ rating with a price target on the stock of $14. The company has a consensus ‘Buy’ rating with a consensus price target of $13.25, all according to Cerbat Gem Market News and Analysis (http://dtn.fm/Ch85p).

Institutional investors and hedge funds are now said to own over 27% of MediWound shares, after Migdal Insurance & Finance Holdings, Wells Fargo & Company MN, and Oppenheimer & Co. bought new positions in the company’s stock. Wellington Management Group LLP and United Services Automobile Association also increased their positions in MediWound. As of this writing, the company has a market cap of $107.17 million, with an enterprise value at $84.15 million, and shares currently selling at around $4.90 per share.

For more information, visit the company’s website at www.mediwound.com